Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...

Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

This leaflet answers some common questions about ENTECAVIR VIATRIS. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Viatris' earnings beat was driven by effective cost management. For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023 .

Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...

As Leo stands in his office, overseeing the entrance of Viatris' bustling office in the Netherlands, he reflects on the 50 years that have shaped his journey with the company. From his early days ...

Shares of Viatris Inc. VTRS slumped 0.24% to $12.42 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 5,868.55 and ...